The Role of FLT3 Kinase as an AML Therapy Target

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|19|2758-2765

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.19, 2012-06, pp. : 2758-2765

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia

By  

Current Pharmaceutical Design, Vol. 10, Iss. 16, 2004-06 ,pp. : 1867-1883

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

By Tickenbrock Lara   Müller-Tidow Carsten   Berdel Wolfgang E   Serve Hubert  

Expert Opinion on Emerging Drugs, Vol. 11, Iss. 1, 2006-03 ,pp. : 153-165

Informa Healthcare

Access to resources Recommend Favorite

Novel FLT3 tyrosine kinase inhibitors

By Levis Mark   Small Donald  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 12, 2003-12 ,pp. : 1951-1962

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule FLT3 Tyrosine Kinase Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1183-1193

Bentham Science Publishers

Access to resources Recommend Favorite

FLT3 as a Therapeutic Target in Childhood Acute Leukemia

By  

Current Drug Targets, Vol. 8, Iss. 6, 2007-06 ,pp. : 703-714

Bentham Science Publishers

Access to resources Recommend Favorite